Janux Therapeutics, Inc. Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest
Janux Therapeutics, Inc. (JANX) reported Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$24.85 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-06
- Janux Therapeutics, Inc. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$24.85M.
- Janux Therapeutics, Inc. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$28.10M.
- Janux Therapeutics, Inc. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$32.19M.
- Janux Therapeutics, Inc. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$23.50M.
- Janux Therapeutics, Inc. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2025 was -$111.47M.
- Janux Therapeutics, Inc. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2024 was -$67.50M.
- Janux Therapeutics, Inc. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2023 was -$56.09M.
- Janux Therapeutics, Inc. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2022 was -$64.32M.
| Period end | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month as first filed | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$24.85M 10-Q · filed 2026-08-06 | -$52.95M 10-Q · filed 2026-08-06 | -$85.15M derived: sum of 3 quarters · filed 2026-08-06 | -$108.64M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | -$28.10M 10-Q · filed 2026-05-07 | -$60.29M derived: sum of 2 quarters · filed 2026-05-07 | -$83.79M derived: sum of 3 quarters · filed 2026-05-07 | -$117.66M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | -$32.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$55.69M derived: sum of 2 quarters · filed 2026-02-26 | -$89.56M derived: sum of 3 quarters · filed 2026-08-06 | -$111.47M 10-K · filed 2026-02-26 | ||
| 2025-09-30 | -$23.50M 10-Q · filed 2025-11-06 | -$57.37M derived: sum of 2 quarters · filed 2026-08-06 | -$79.28M 10-Q · filed 2025-11-06 | -$105.16M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | -$33.87M 10-Q · filed 2026-08-06 | -$55.78M 10-Q · filed 2026-08-06 | -$81.67M derived: sum of 3 quarters · filed 2026-08-06 | -$100.28M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | -$21.91M 10-Q · filed 2026-05-07 | -$47.80M derived: sum of 2 quarters · filed 2026-05-07 | -$66.41M derived: sum of 3 quarters · filed 2026-05-07 | -$73.46M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | -$25.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$44.50M derived: sum of 2 quarters · filed 2026-02-26 | -$51.55M derived: sum of 3 quarters · filed 2026-02-26 | -$67.50M 10-K · filed 2026-02-26 | ||
| 2024-09-30 | -$18.61M 10-Q · filed 2025-11-06 | -$25.66M derived: sum of 2 quarters · filed 2025-11-06 | -$41.61M 10-Q · filed 2025-11-06 | -$51.53M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-06-30 | -$7.05M 10-Q · filed 2025-08-07 | -$23.00M 10-Q · filed 2025-08-07 | -$32.92M derived: sum of 3 quarters · filed 2026-02-26 | -$44.60M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-03-31 | -$15.95M 10-Q · filed 2025-05-08 | -$25.87M derived: sum of 2 quarters · filed 2026-02-26 | -$37.55M derived: sum of 3 quarters · filed 2026-02-26 | -$55.38M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2023-12-31 | -$9.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$21.60M derived: sum of 2 quarters · filed 2026-02-26 | -$39.43M derived: sum of 3 quarters · filed 2026-02-26 | -$56.09M 10-K · filed 2026-02-26 | ||
| 2023-09-30 | -$11.68M 10-Q · filed 2024-11-06 | -$29.51M derived: sum of 2 quarters · filed 2024-11-06 | -$46.17M 10-Q · filed 2024-11-06 | -$61.50M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-06-30 | -$17.83M 10-Q · filed 2024-08-07 | -$34.49M 10-Q · filed 2024-08-07 | -$49.81M derived: sum of 3 quarters · filed 2025-02-27 | -$66.88M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-03-31 | -$16.66M 10-Q · filed 2024-05-08 | -$31.99M derived: sum of 2 quarters · filed 2025-02-27 | -$49.05M derived: sum of 3 quarters · filed 2025-02-27 | -$66.28M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2022-12-31 | -$15.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$32.39M derived: sum of 2 quarters · filed 2025-02-27 | -$49.62M derived: sum of 3 quarters · filed 2025-02-27 | -$64.32M 10-K · filed 2025-02-27 | ||
| 2022-09-30 | -$17.07M 10-Q · filed 2023-11-07 | -$34.29M derived: sum of 2 quarters · filed 2023-11-07 | -$49.00M 10-Q · filed 2023-11-07 | -$62.98M derived: sum of 4 quarters · filed 2023-11-07 | ||
| 2022-06-30 | -$17.23M 10-Q · filed 2023-08-08 | -$31.93M 10-Q · filed 2023-08-08 | -$45.91M derived: sum of 3 quarters · filed 2023-08-08 | -$56.67M derived: sum of 4 quarters · filed 2023-08-08 | ||
| 2022-03-31 | -$14.98M 10-Q · filed 2023-05-09 | -$28.69M derived: sum of 2 quarters · filed 2023-05-09 | -$39.45M derived: sum of 3 quarters · filed 2023-05-09 | -$45.63M derived: sum of 4 quarters · filed 2023-05-09 | ||
| 2021-12-31 | -$13.71M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | -$24.47M derived: sum of 2 quarters · filed 2023-03-10 | -$30.66M derived: sum of 3 quarters · filed 2023-03-10 | -$32.94M 10-K · filed 2023-03-10 | ||
| 2021-09-30 | -$10.76M 10-Q · filed 2022-11-10 | -$16.95M derived: sum of 2 quarters · filed 2022-11-10 | -$19.23M 10-Q · filed 2022-11-10 | -$20.89M derived: sum of 4 quarters · filed 2022-11-10 | ||
| 2021-06-30 | -$6.19M 10-Q · filed 2022-08-09 | -$6.22M 10-Q · filed 2021-08-10 | -$8.47M 10-Q · filed 2022-08-09 | -$8.51M 10-Q · filed 2021-08-10 | -$10.13M derived: sum of 3 quarters · filed 2022-08-09 | -$11.38M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$2.28M 10-Q · filed 2022-05-10 | -$3.94M derived: sum of 2 quarters · filed 2022-05-10 | -$5.20M derived: sum of 3 quarters · filed 2022-05-10 | -$7.66M derived: sum of 4 quarters · filed 2022-05-10 | ||
| 2020-12-31 | -$1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | -$2.91M derived: sum of 2 quarters · filed 2022-03-18 | -$5.37M derived: sum of 3 quarters · filed 2022-03-18 | -$6.78M 10-K · filed 2022-03-18 | ||
| 2020-09-30 | -$1.26M 10-Q · filed 2021-11-09 | -$3.72M derived: sum of 2 quarters · filed 2021-11-09 | -$5.13M 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | -$2.46M 10-Q · filed 2021-08-10 | -$3.87M 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |